Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab + Chemo + Endostatin in Operable NSCLC
NCT05360979Phase 2Unknown
- Sponsor
- The Second Xiangya Hospital
- Start
- May 2022
- Primary completion
- May 2023
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab in non-small cell lung cancer (NSCLC), sponsored by The Second Xiangya Hospital. Status: unknown.
02
Drugs
envafolimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05360979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05360979.